New hope for multiple myeloma patients Who've run out of options

NCT ID NCT06630806

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This is the first human study of an experimental antibody drug called SAR446523 for people with multiple myeloma that has returned or stopped responding to other treatments. The trial aims to find the safest and most effective dose by testing different amounts in about 87 participants. Researchers will closely monitor how patients respond to the treatment and track any side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hackensack Meridian Health - Hackensack University Medical Center- Site Number : 8400001
RECRUITING

Hackensack, New Jersey, 07601, United States
Investigational Site Number : 0360001
RECRUITING

Wollongong, New South Wales, 2500, Australia
Investigational Site Number : 0360002
RECRUITING

Melbourne, Victoria, 3065, Australia
Investigational Site Number : 1240001
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Investigational Site Number : 1240002
RECRUITING

Sherbrooke, Quebec, J1H 5N4, Canada
Investigational Site Number : 1240005
RECRUITING

Vancouver, British Columbia, V5Z 1L3, Canada
Investigational Site Number : 2500001
RECRUITING

Nantes, 44093, France
Investigational Site Number : 2500002
RECRUITING

Lille, 59037, France
Investigational Site Number : 3760001
RECRUITING

Tel Aviv, Malopolskie, 6423906, Israel
Investigational Site Number : 3760002
RECRUITING

Jerusalem, 9112001, Israel
Investigational Site Number : 3760004
RECRUITING

Haifa, 3109601, Israel
Investigational Site Number : 3800001
RECRUITING

Rozzano, Milano, 20089, Italy
Investigational Site Number : 3800002
RECRUITING

Torette, Ancona, 60020, Italy
Investigational Site Number : 7240001
RECRUITING

Madrid, 28040, Spain
Investigational Site Number : 7240002
RECRUITING

Barcelona, Barcelona [Barcelona], 08035, Spain
Mayo Clinic in Arizona - Phoenix- Site Number : 8400005
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic in Florida- Site Number : 8400003
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic in Rochester - Minnesota- Site Number : 8400004
RECRUITING

Rochester, Minnesota, 55905, United States
Thomas Jefferson University Hospital- Site Number : 8400002
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

Conditions

Explore the condition pages connected to this study.

PLASMA CELL MYELOMA REFRACTORY